Yasuaki Arai, MD

11/12/2019

Transarterial Chemoembolization with Durvalumab or Durvalumab + Bevacizumab in Patients with Locoregional Hepatocellular Carcinoma: EMERALD-1

Purpose: Because curative therapy is not always feasible and there is no standard systemic therapy, patients with intermediate-stage hepatocellular carcinoma (HCC) are treated with locore...

Shukui Qin , MD, PhD;

Zhenggang Ren ;

Joseph Erinjeri ;

Shethah Morgan ;

Gordon Cohen ;

Yasuaki Arai , MD;

Riccardo Lencioni , MD;

Bruno Sangro , MD, PhD;

Stephen Lam Chan , MD;

Masatoshi Kudo , MD, PhD;

10/21/2019

CIO 2020-4 Transarterial Chemoembolization Combined With Durvalumab±Bevacizumab in Patients With Locoregional HCC (EMERALD-1)

Yasuaki Arai , MD;

Zhenggang Ren ;

Joseph Erinjeri ;

Philip He ;

Shethah Morgan ;

Gordon Cohen ;

Riccardo Lencioni , MD;

Bruno Sangro , MD, PhD;

Masatoshi Kudo , MD, PhD;

Stephen Lam Chan , MD;

Shukui Qin , MD, PhD;

07/23/2021

Balloon-Occluded TACE: My Top 5 Technical Pearls

Yasuaki Arai , MD;

02/07/2022

Catheter Sticking to the Orifice of the IMMA With Glue

Yasuaki Arai , MD;

02/17/2022

Catastrophic Complication: Case 1

Ziv J. Haskal, MD , MD;

Yolanda Bryce , MD, RPVI;

Yasuaki Arai , MD;

Siddharth A. Padia , MD;

Raul N. Uppot , MD;

Isabel Newton , MD, PhD;

Anil Kurup , MD;

Alessandro Lunardi , MD;

11/12/2019

Featured CME Course

Targeted Therapies for the Management of Chronic Lymphocytic Leukemia: Evaluating the Evidence to Optimize Patient Care and Outcomes

Upcoming Events

February 2 ⁠–⁠ February 5

February 7 ⁠–⁠ February 9

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

March 22 ⁠–⁠ March 23

March 27 ⁠–⁠ March 30

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

April 30 ⁠–⁠ May 4

May 1 ⁠–⁠ May 3

See Full Calendar

Yasuaki Arai, MD

Featured CME Course

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products